| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 10% | $54,973,720 | 25,931,000 | Vivo Opportunity Fund Holdings, L.P. | 29 Sep 2025 | |||
| Woodline Partners LP | 9.9% | $14,323,021 | 7,125,881 | Woodline Partners LP | 30 Sep 2025 | |||
| BIOTECHNOLOGY VALUE FUND L P | 9.1% | -8.9% | $18,761,910 | -$1,598,505 | 4,761,906 | -7.9% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| Commodore Capital LP | 9.9% | $9,588,711 | 4,522,977 | Commodore Capital LP | 26 Sep 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $9,331,180 | 4,401,500 | RA Capital Management, L.P. | 26 Sep 2025 | |||
| PERCEPTIVE ADVISORS LLC | 7.3% | $13,088,916 | 3,471,861 | Perceptive Advisors LLC | 14 Jan 2026 | |||
| RTW INVESTMENTS, LP | 3.2% | -68% | $6,253,970 | +$2,218,090 | 1,587,302 | +55% | RTW Investments, LP | 31 Dec 2025 |
As of 31 Dec 2025, 48 institutional investors reported holding 36,342,111 shares of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS). This represents 69% of the company’s total 52,328,637 outstanding shares.
The largest institutional shareholders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) together control 69% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 22% | 11,420,000 | 0% | 2.8% | $42,710,800 |
| Commodore Capital LP | 8.4% | 4,401,500 | 0% | 1.1% | $16,461,610 |
| RA CAPITAL MANAGEMENT, L.P. | 8.4% | 4,401,500 | 0% | 0.17% | $16,461,610 |
| Woodline Partners LP | 5.4% | 2,850,881 | 0% | 0.04% | $10,662,295 |
| Spruce Street Capital LP | 4.2% | 2,198,502 | 0% | 2.7% | $8,222,397 |
| Sessa Capital IM, L.P. | 4.2% | 2,198,457 | 0% | 0.16% | $8,222,229 |
| Blackstone Inc. | 4.1% | 2,143,585 | 0.04% | $8,017,008 | |
| VANGUARD GROUP INC | 3.5% | 1,847,136 | +405% | 0% | $6,908,288 |
| PERCEPTIVE ADVISORS LLC | 1.5% | 803,210 | 0.06% | $3,004,005 | |
| Propel Bio Management, LLC | 1.2% | 652,881 | 2.1% | $2,441,775 | |
| Jefferies Financial Group Inc. | 1.1% | 580,328 | 0.02% | $2,170,427 | |
| Balyasny Asset Management L.P. | 0.91% | 475,439 | 0% | $1,778,142 | |
| MILLENNIUM MANAGEMENT LLC | 0.62% | 324,090 | 0% | $1,212,097 | |
| HB Wealth Management, LLC | 0.59% | 307,500 | 0% | 0.01% | $1,150,050 |
| AMERIPRISE FINANCIAL INC | 0.54% | 283,645 | 0% | $1,060,833 | |
| MARSHALL WACE, LLP | 0.45% | 236,460 | 0% | $884,360 | |
| Simplify Asset Management Inc. | 0.4% | 208,227 | 0.01% | $778,769 | |
| AWM Investment Company, Inc. | 0.38% | 200,000 | 0% | 0.07% | $748,000 |
| STEMPOINT CAPITAL LP | 0.28% | 146,558 | 0.09% | $548,127 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.23% | 119,517 | +39% | 0% | $447,037 |
| ExodusPoint Capital Management, LP | 0.16% | 86,113 | 0% | $322,063 | |
| GOLDMAN SACHS GROUP INC | 0.1% | 51,348 | +358% | 0% | $192,042 |
| Pathstone Holdings, LLC | 0.1% | 50,650 | 0% | 0% | $189,433 |
| OMERS ADMINISTRATION Corp | 0.08% | 42,000 | 0% | $157,080 | |
| Qube Research & Technologies Ltd | 0.06% | 31,147 | 0% | $116,490 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 36,342,111 | $135,919,535 | +$25,718,819 | $3.74 | 48 |
| 2025 Q3 | 28,023,938 | $56,328,113 | +$52,469,483 | $2.01 | 34 |
| 2025 Q2 | 1,923,874 | $3,369,565 | -$378,633 | $1.76 | 25 |
| 2025 Q1 | 2,209,552 | $2,994,479 | -$1,776,863 | $1.36 | 26 |
| 2024 Q4 | 2,652,300 | $10,189,778 | -$1,266,185 | $3.79 | 26 |
| 2024 Q3 | 3,141,736 | $8,482,377 | +$68,507 | $2.70 | 24 |
| 2024 Q2 | 3,127,151 | $9,694,108 | -$923,501 | $3.10 | 21 |
| 2024 Q1 | 3,339,666 | $15,162,138 | -$15,603,353 | $4.54 | 23 |
| 2023 Q4 | 8,791,109 | $6,055,351 | +$6,055,351 | $0.69 | 3 |